Charles Schwab Investment Management Inc Candel Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 52,190 shares of CADL stock, worth $390,381. This represents 0.0% of its overall portfolio holdings.
Number of Shares
52,190
Previous 46,777
11.57%
Holding current value
$390,381
Previous $324,000
39.81%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CADL
# of Institutions
77Shares Held
15.6MCall Options Held
981KPut Options Held
521K-
Baker Bros. Advisors LP New York, NY2.98MShares$22.3 Million0.29% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.94MShares$14.5 Million9.1% of portfolio
-
Northpond Ventures, LLC1.94MShares$14.5 Million48.35% of portfolio
-
Braidwell LP Stamford, CT1.6MShares$12 Million0.78% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.34MShares$10 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $216M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...